Relation of baseline prostate volume to improvement of lower urinary tract symptoms due to tamsulosin monotherapy in benign prostatic hyperplasia: An exploratory, multicenter, prospective study

Conclusions: PV is an important prognostic factor affecting the improvement of the LUTS by α1-blocker monotherapy. Tamsulosin monotherapy may not be enough for large prostate (>40 mg) to maintain adequate symptom relief, and it is better to start with other medical options such as combined therapy or early nonmedical therapy. Starting α1-blocker monotherapy in smaller prostates may be of benefit in symptomatic patients without considering watchful waiting.

Source: Urology Annals - July 16, 2020 Category: Urology & Nephrology Authors: Mahmoud Shoukry El-Adawy Ahmed Yehia Abdelaziz Ahmed Salem Waseem Aboul Ela Ayman Salah Moussa Rabee Ibrahim Fouad Zanaty Mohamed H Abdelhamid Hussien Aldaqadossi Ahmed M Ragheb Hossam A Shaker Sameh Kotb Source Type: research